Clinical course of XXXX with survival to advanced age.

@entity1 @entity1121 @entity944
OBJECTIVES: This study was designed to clarify and resolve the clinical profile of older @entity1 with @entity1121 ( @entity1121 ). BACKGROUND: Adverse consequences of @entity1121 such as @entity944 and incapacitating symptoms have been emphasized for the young and middle-aged. METHODS: Long-term outcome of @entity1121 was assessed in a community-based cohort not subject to tertiary center referral bias. RESULTS: Of 312 @entity1 , 73 (23%) achieved normal life expectancy (> or =75 years; range to 96); 44 (14%) were > or =80 years old. Most @entity1 > or =75 years (47; 64%) experienced no or only mild limiting symptoms and lived virtually their entire lives with few @entity1121 -related clinical consequences; 26 @entity1 (36%) experienced severe progressive symptoms. In elderly @entity1 with @entity1121 , diagnosis and symptom onset were considerably delayed to 74 +/- 8 and 70 +/- 11 years, respectively. For @entity1 > or =50 years at diagnosis, the probability of survival for 5, 10, and 15 years was 85 +/- 3%, 74 +/- 4%, and 57 +/- 6%, respectively, and did not significantly differ from a matched general population (p = 0.20). @entity1 > or =75 years were predominantly @entity1 , and had less marked wall thickness and more frequently showed basal outflow obstruction > or =30 mm Hg (compared with those <75 years; p < 0.01 and 0.001, respectively). CONCLUSIONS: @entity1121 is frequently well tolerated and compatible with normal life expectancy, and may remain clinically dormant for long periods of time with symptoms and initial diagnosis deferred until late in life. These observations afford a measure of reassurance to many @entity1 with @entity1121 , a disease for which clinical course is often unfavorable and unpredictable.
